+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways

  • ID: 4845425
  • Report
  • 488 Pages
  • Roots Analysis
1 of 5

FEATURED COMPANIES

  • 3W Partners
  • BioMedical Catalyst Fund
  • European Research Council
  • Lilly Asia Ventures
  • Pharmacyclics
  • SyntheX Labs
  • MORE

Cancer is known to be one of the leading causes of death worldwide. In the US, 0.6 million deaths were reported to have been caused due to cancer in 2018 alone. Further, according to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million.  It is worth mentioning that in the past five years, the United States Food and Drug Administration (USFDA) has approved more than 100 drugs for the treatment of different types of cancer. However, as the growing global population is gradually being exposed to a growing list of risk factors and cancer causing agents, there is a pressing need for more specific and potent drugs / therapies to combat this complex, life threatening clinical condition.  Over time, conventional treatment options, such as chemotherapy, surgery and radiation therapy, have shown limited efficacy in treating late-stage cancers. In addition, the non-specific and highly toxic nature of these therapies have severe detrimental effects on patients’ quality of life.

Defects in deoxyribonucleic acid (DNA) repair have been shown to be one of the primary causes of cancer. Moreover, tumor cells that are characterized by impaired DNA repair pathways typically become reliant on alternative DNA repair pathways for survival. This phenomenon is commonly referred to as oncogene addiction.  Inhibitors of such compensatory repair pathways have the potential to sensitize cancer cells to DNA damaging agents and other therapeutic regimens. On the other hand, the simultaneous inactivation of certain pairs of genes have been shown to cause cell death. This phenomenon is known as synthetic lethality. In cancers, where mutations have led to the loss of function of one gene, using a drug molecule that specifically targets the corresponding gene of the synlet pair has been demonstrated to be a viable and effective therapeutic regimen. Recent advances in biomarker research, including the development of companion diagnostics, in combination with modern molecular screening platforms, which include clustered regularly interspaced short palindromic repeats (CRISPR)- and RNA interference (RNAi)-based screening techniques, have led to the identification of a number of synthetically lethal gene pairs.

Currently, there are four approved (and marketed) poly-ADP ribose polymerase (PARP) inhibitor drugs, which have been shown to operate based on the concept of synthetic lethality. Further, several such drugs are being investigated for the treatment of a myriad of advanced oncological and non-oncological indications. A number of companies are engaged in this domain; moreover, both venture capital (VC) firms and government bodies are actively funding such research initiatives.

Scope of the Report

The ‘Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways’ report features an extensive study of the current market landscape and the future potential of the synthetic lethality-based therapeutics. It features an in-depth analysis, highlighting the capabilities of various companies engaged in this domain. In addition to other elements, the study includes:

  • A detailed assessment of the current market landscape, providing information on drug developer(s) (year of establishment, headquarters and size of the company), phase of development (marketed, clinical, preclinical, and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s), target indication(s), and route of administration. In addition, the chapter includes a list of screening platforms that are being used by industry players to study synlet interactions between gene pairs.
  • Detailed profiles of large players that are engaged in the development of synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products), featuring a brief overview of the company, its financial information (if available), detailed profiles of their respective lead drug candidates, and an informed future outlook. Additionally, each drug profile features information on the type of drug, route of administration, target indications, current status of development and an excerpt on its developmental history. In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of the executive team), recent developments, along with descriptions of their synthetic lethality-based drug candidates.
  • An analysis of the prevalent and emerging trends in this domain, as represented on the social media platform, Twitter, posted during the period 2010-2019 (till May), highlighting the historical trend of tweets, most prolific contributors, frequently discussed synlet targets, popular disease indications and a multivariate tweet benchmark analysis.
  • An analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May), highlighting the research focus within this niche industry segment. It includes an informed opinion on the key trends observed across the aforementioned publications, including information on target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor).
  • An analysis of various abstracts presented at the American Society of Clinical Oncology (ASCO) in the time period 2013-2019 (till May), highlighting several parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of number of published abstracts). In addition, this analysis features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on the number of publications, citation count and research gate score.
  • An in-depth analysis of close to 750 grants that have been awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May), highlighting various important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers. It also features a detailed analysis on most popular synlet targets and target indications, along with a multivariate grant attractiveness analysis based on parameters, such as amount awarded, support period, grant type, number of synlet targets and number of indications under study.
  • An analysis of the investments made into companies that have proprietary synthetic lethality-based drugs / screening platforms, including seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings.
  • An in-depth benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government fundings, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated). Further, it highlights the long-term opportunities (for drug developers) associated with individual targets, based on their popularity across different portals.
  • An analysis of the role of innovative companion diagnostics in synthetic lethality on the basis of several parameters, such as synlet target, drug candidate(s) being investigated, target biomarker(s), target disease indication(s) and assay technique used. It also includes case studies, highlighting those companion diagnostic tests that are available and are being used to evaluate the therapeutic efficiency of approved PARP inhibitors using the principle of synthetic lethality.

One of the key objectives of the report was to estimate the existing market size and identify the future opportunity for synthetic lethality-based drugs, over the next decade. Based on multiple parameters, such as target consumer segments, region-specific disease prevalence, anticipated adoption of the marketed and late stage drugs and the likely selling price, we have provided informed estimates on the evolution of the market over the period 2019-2030. The report includes potential sales forecast of drugs that are currently marketed or are in late stages of development (phase II and above). The report also features the likely distribution of the current and forecasted opportunity across [A] type of molecules (small molecule and biologic), [B] different target indications (breast cancer, colorectal cancer, fallopian tube cancer, gastric cancer, head and neck cancer, lung cancer, ovarian cancer, peritoneal cancer and others), [C] synlet targets (APE1 / Ref-1, Chk1, GLS1, PARP, Pol θ, PP2A and Wee1), [D] route of administration (oral and intravenous), and [E] key geographical regions (North America, EU5, Asia-Pacific and Rest of the World). To account for the uncertainties associated with the growth of synthetic lethality-based drugs market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were also influenced by discussions conducted with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order of company names):

  • Simon Boulton (Vice President, Science Strategy, Artios Pharma)
  • Yi Xu (Associate Director, Business Development, IMPACT Therapeutics)
  • Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School)
  • Vivek Dharwal (Professor, Department of Biochemistry, Panjab University)
  • Alfred Nijkerk (Chief Executive Officer, UbiQ)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3W Partners
  • BioMedical Catalyst Fund
  • European Research Council
  • Lilly Asia Ventures
  • Pharmacyclics
  • SyntheX Labs
  • MORE

1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines

2 EXECUTIVE SUMMARY

3 INTRODUCTION TO DNA DAMAGE AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. Overview of Deoxyribonucleic Acid (DNA) Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of DNA Repair System
3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.1.1. Photoreactivation
3.5.1.2. Alkyl Transferase Mediated Direct DNA Repair
3.5.1.3. AlkB Mediated Direct DNA Repair
3.5.1.4. DNA Ligase Mediated Direct DNA Repair
3.5.2. Excision Repair
3.5.2.1. Base Excision Repair (BER)
3.5.2.1.1. BER Pathway: Key Enzymes
3.5.2.1.1.1. DNA Glycosylases
3.5.2.1.1.2. Apurinic / Apyrimidinic (AP) Endonucleases
3.5.2.1.1.3. Other Enzymes
3.5.2.1.2. Short-Patch Base Excision Repair
3.5.2.1.3. Long-Patch Base Excision Repair
3.5.2.2. Nucleotide Excision Repair (NER)
3.5.2.3. Mismatch Repair
3.5.3. Indirect Repair
3.5.3.1. Homologous Recombination Repair (HRR)
3.5.3.2. Non-Homologous End-Joining
3.6. Mutations in DNA Repair Genes

4 INTRODUCTION TO SYNTHETIC LETHALITY
4.1. Chapter Overview
4.2. Concept of Synthetic Lethality
4.2.1. Historical Evolution of Synthetic Lethality
4.2.2. HRR and Synthetic Lethality
4.2.3. Other Synthetic Lethal Gene Interactions
4.2.4. Gene Interactions beyond Synthetic Lethality
4.2.5. Applications of Synthetic Lethality
4.2.6. Limitations of Synthetic Lethality
4.3. Identification of Synlet Interactions
4.3.1. Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Based Synlet Target Identification
4.3.2. RNA Interference (RNAi) Based Synlet Target Identification
4.3.3. Other Screening Platforms for Synlet Target Identification
4.4. Prevalent Trends Related to Synthetic Lethality
4.4.1. Recent News on Google: Emerging Focus Areas
4.4.2. Google Trends Analysis: Historical Timeline
4.4.3. Google Trends Analysis: Geographical Activity
4.4.4. Google Trends Analysis: Co-Relation with Other Therapeutic Areas
4.5 Concluding Remarks

5 MARKET OVERVIEW
5.1. Chapter Overview
5.2. Synthetic Lethality-based Drugs: Marketed and Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Type of Therapy
5.2.4. Analysis by Type of Synlet Target
5.2.5. Analysis by Type of Patient Segment
5.2.6. Analysis by Therapeutic Area
5.2.7. Analysis by Target Indication
5.2.8. Analysis by Route of Administration
5.3. Synthetic Lethality-based Drugs: List of Drug Developers
5.3.1. Analysis by Year of Establishment
5.3.2. Analysis by Location of Headquarters
5.3.3. Analysis by Company Size
5.3.4. Analysis by Company Size and Location of Headquarters

6 COMPANY PROFILES
6.1. Chapter Overview
6.2. Profiles of Established Players
6.2.1. AbbVie
6.2.1.1. Company Overview
6.2.1.2. Synthetic Lethality-based Drug Portfolio
6.2.1.2.1. Veliparib (ABT-888)
6.2.1.3. Recent Developments and Future Outlook
6.2.2. AstraZeneca
6.2.2.1. Company Overview
6.2.2.2. Synthetic Lethality-based Drug Portfolio
6.2.2.2.1. Olaparib (Lynparza®)
6.2.2.2.2. AZD6738
6.2.2.2.3. AZD1775
6.2.2.3. Recent Developments and Future Outlook
6.2.3. BeiGene
6.2.3.1. Company Overview
6.2.3.2. Synthetic Lethality-based Drug Portfolio
6.2.3.2.1. Pamiparib (BGB-290)
6.2.3.3. Recent Developments and Future Outlook
6.2.4. Clovis Oncology
6.2.4.1. Company Overview
6.2.4.2. Synthetic Lethality-based Drug Portfolio
6.2.4.2.1. Rucaparib (Rubraca®)
6.2.4.3. Recent Developments and Future Outlook
6.2.5. GlaxoSmithKline
6.2.5.1. Company Overview
6.2.5.2. Synthetic Lethality-based Drug Portfolio
6.2.5.2.1. Niraparib (Zejula®)
6.2.5.3. Recent Developments and Future Outlook
6.2.6. Pfizer
6.2.6.1. Company Overview
6.2.6.2. Synthetic Lethality-based Drug Portfolio
6.2.6.2.1. Talazoparib (TALZENNA®)
6.2.6.3. Recent Developments and Future Outlook
6.3. Profiles of Small and Mid-Sized Players
6.3.1. AtlasMedx
6.3.2. Chordia Therapeutics
6.3.3. IDEAYA Biosciences
6.3.4. Mission Therapeutics
6.3.5. Repare Therapeutics
6.3.6. Sierra Oncology
6.3.7. SyntheX Labs

7 EMERGING TRENDS ON SOCIAL MEDIA
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Synthetic Lethality: Trends on Twitter
7.3.1. Cumulative Year-Wise Activity
7.3.2. Historical Trends in Volume of Tweets
7.3.3. Evolutionary Trend Analysis
7.3.4. Trending Words / Phrases on Twitter
7.3.5. Most Prolific Contributors on Twitter
7.3.6. Most Popular Synlet Targets / Patient Mutations on Twitter
7.3.7. Most Popular Indications on Twitter
7.3.8. Heat Map Analysis: Distribution by Synlet Targets / Patient Mutations and Indications
7.4. Most Popular Tweets
7.5. Concluding Remarks

8 PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Synthetic Lethality: List of Recent Publications, 2019
8.3.1. Analysis by Type of Publication
8.3.2. Analysis by Study Objective
8.4. Synthetic Lethality: Publication Analysis, 2017–2019
8.4.1. Analysis by Year of Publication
8.4.2. Emerging Focus Areas
8.4.3. Analysis by Synlet Targets / Patient Mutations
8.4.3.1. Most Popular Synlet Targets / Patient Mutations
8.4.3.2. Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
8.4.4. Analysis by Target Indications
8.4.4.1. Most Popular Target Indications
8.4.4.2. Year-Wise Trend in Activity for Popular Target Indications
8.4.5. Analysis by Key Research Journals
8.4.5.1. Key Journals Based on Number of Publications
8.4.5.2. Analysis by Journal Impact Factor
8.4.5.3. Key Journals Based on Journal Impact Factor
8.4.6. Key Research Hubs
8.4.7. Most Popular Authors
8.4.8. Analysis of Publications with Grant Support
8.4.8.1. Most Popular Grant Bodies
8.4.8.2. Location of Grant Bodies
8.5. Publication Benchmark Analysis

9 ABSTRACT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Synthetic Lethality: List of American Society of Clinical Oncology Abstracts
9.3.1. Analysis by Year of Publication
9.3.2. Emerging Focus Areas
9.3.3. Most Popular Drugs
9.3.4. Most Popular Synlet Targets / Patient Mutations
9.3.5. Most Popular Target Indications
9.3.6. Most Popular Principal Authors
9.3.6.1. Analysis by Locations of Principal Authors
9.4.6.2. Analysis by Industry Type of Principal Authors
9.4.6.3. Analysis by Active Organization
9.4.6.4. Analysis by Author Designation
9.4.6.5. Most Popular Authors

10 ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Synthetic Lethality: List of Grants Awarded by National Institutes of Health
10.3.1. Analysis by Year of Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering Institute Center
10.3.4. Analysis by Funding Institute Center
10.3.5. Analysis by Support Period
10.3.6. Analysis by Funding Institute Center and Support Period
10.3.7. Most Popular National Institute of Health (NIH) Spending Sectors
10.3.8. Analysis by Funding Mechanism
10.3.9. Analysis by Emerging Focus Areas
10.3.10. Most Popular Synlet Targets / Patient Mutations
10.3.11. Most Popular Target Indications
10.3.12. Analysis by Type of Grant Application
10.3.13. Most Popular NIH Departments
10.3.14. Analysis by Study Section
10.3.15. Analysis by Type of Recipient Organization
10.3.16. Most Popular Recipient Organization
10.3.17. Most Popular Recipient Organization and NIH Spending Sectors
10.3.18. Analysis by Grant Activity
10.3.19. Most Prominent Project Leaders
10.3.20. Regional Distribution of Recipient Organization
10.4. Grant Attractiveness Analysis

11 FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Synthetic Lethality: List of Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Synlet Target
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Target Indication
11.3.10. Analysis by Geography
11.3.11. Most Active Players
11.4. Concluding Remarks

12 TARGET BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Target Benchmark Analysis
12.3.1. Clinically Validated Synlet Targets
12.3.2. Preclinically Validated Synlet Targets
12.3.3. Early Stage Research Validated Synlet Targets
12.4. Initiatives of Big Pharmaceutical Players
12.5. Concluding Remarks

13 ROLE OF COMPANION DIAGNOSTICS IN SYNTHETIC LETHALITY
13.1. Chapter Overview
13.2. Concept of Companion Diagnostics
13.3. Development of Companion Diagnostics
13.3.1. Co-development / Parallel Development Approach
13.3.2. Development of Companion Diagnostics Post Drug Approval
13.3.3. Development of already Approved Companion Diagnostics for New Drugs / Disease Indications
13.4. Advantages of Companion Diagnostics
13.5. Applications of Companion Diagnostics in Synthetic Lethality
13.6. Companion Diagnostics: List of Available / Under Development Tests
13.6.1. Analysis by Synlet Target
13.6.2. Analysis by Type of Biomarker
13.6.3. Analysis by Type of Biomarker and Technology
13.6.4. Analysis by Target Indication
13.6.5. Analysis by Developer and Synlet Target
13.6.6. Most Prominent Developers
13.7. Case-in-Point: Companion Diagnostics for Commercially Available Poly-ADP Ribose Polymerase (PARP) Inhibitors
13.7.1. Companion Diagnostics Test for Niraparib
13.7.1.1. Product Overview
13.7.1.2. Working Process
13.7.1.3. Collaborations
13.7.2. Companion Diagnostics Test for Olaparib
13.7.2.1. Product Overview
13.7.2.2. Working Process
13.7.2.3. Collaborations
13.7.3. Companion Diagnostics Test for Rucaparib
13.7.3.1. Product Overview
13.7.3.2. Collaborations
13.7.4. Companion Diagnostics Test for Talazoparib
13.7.4.1. Product Overview
13.7.4.2. Collaborations
13.8. Future Perspective

14 MARKET FORECAST
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Forecast Methodology and Key Assumptions
14.4. Overall Synthetic Lethality-based Drugs Market, 2019-2030
14.4.1. Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019-2030
14.4.1.1 Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030
14.4.1.2 Synthetic Lethality-based Drugs Market for Biologic, 2019-2030
14.4.2. Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019-2030
14.4.2.1 Synthetic Lethality-based Drugs Market for APE1 / Ref-1, 2019-2030
14.4.2.2 Synthetic Lethality-based Drugs Market for Chk, 2019-2030
14.4.2.3 Synthetic Lethality-based Drugs Market for GLS1, 2019-2030
14.4.2.4 Synthetic Lethality-based Drugs Market for PARP, 2019-2030
14.4.2.5 Synthetic Lethality-based Drugs Market for Pol θ, 2019-2030
14.4.2.6 Synthetic Lethality-based Drugs Market for PP2A, 2019-2030
14.4.2.7 Synthetic Lethality-based Drugs Market for Wee1, 2019-2030
14.4.3. Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019-2030
14.4.3.1 Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030
14.4.3.2 Synthetic Lethality-based Drugs Market for Colorectal Cancer, 2019-2030
14.4.3.3 Synthetic Lethality-based Drugs Market for Fallopian Tube Cancer, 2019-2030
14.4.3.4 Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030
14.4.3.5 Synthetic Lethality-based Drugs Market for Head and Neck Cancer, 2019-2030
14.4.3.5 Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030
14.4.3.7 Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030
14.4.3.8 Synthetic Lethality-based Drugs Market for Peritoneal Cancer, 2019-2030
14.4.3.9 Synthetic Lethality-based Drugs Market for Others, 2019-2030
14.4.4. Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019-2030
14.4.4.1 Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030
14.4.4.2 Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030
14.4.5. Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019-2030
14.4.5.1. Synthetic Lethality-based Drugs Market in the US, 2019-2030
14.4.5.2. Synthetic Lethality-based Drugs Market in France, 2019-2030
14.4.5.3. Synthetic Lethality-based Drugs Market in Germany, 2019-2030
14.4.5.4. Synthetic Lethality-based Drugs Market in Italy, 2019-2030
14.4.5.5. Synthetic Lethality-based Drugs Market in Spain, 2019-2030
14.4.5.6. Synthetic Lethality-based Drugs Market in the UK, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market in Australia, 2019-2030
14.4.5.7. Synthetic Lethality-based Drugs Market in China, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market in Japan, 2019-2030
14.4.6. Product-wise Sales Forecast
14.4.6.1 Niraparib (GlaxoSmithKline)
14.4.6.1.1. Target Patient Population
14.4.6.1.2. Sales Forecast (USD Million)
14.4.6.1.3. Net Present Value (USD Million)
14.4.6.1.4. Value Creation Analysis
14.4.6.2. Olaparib (AstraZeneca)
14.4.6.2.1. Target Patient Population
14.4.6.2.2. Sales Forecast (USD Million)
14.4.6.2.3. Net Present Value (USD Million)
14.4.6.2.4. Value Creation Analysis
14.4.6.3. Rucaparib (Clovis Oncology)
14.4.6.3.1. Target Patient Population
14.4.6.3.2. Sales Forecast (USD Million)
14.4.6.3.3. Net Present Value (USD Million)
14.4.6.3.4. Value Creation Analysis
14.4.6.4. Talazoparib (Pfizer)
14.4.6.4.1. Target Patient Population
14.4.6.4.2. Sales Forecast (USD Million)
14.4.6.4.3. Net Present Value (USD Million)
14.4.6.4.4. Value Creation Analysis
14.4.6.5. Pamiparib (BeiGene)
14.4.6.5.1. Target Patient Population
14.4.6.5.2. Sales Forecast (USD Million)
14.4.6.5.3. Net Present Value (USD Million)
14.4.6.5.4. Value Creation Analysis
14.4.6.6. Veliparib (AbbVie)
14.4.6.6.1. Target Patient Population
14.4.6.6.2. Sales Forecast (USD Million)
14.4.6.6.3. Net Present Value (USD Million)
14.4.6.6.4. Value Creation Analysis
14.4.6.7. Adavosertib (AstraZeneca)
14.4.6.7.1. Target Patient Population
14.4.6.7.2. Sales Forecast (USD Million)
14.4.6.7.3. Net Present Value (USD Million)
14.4.6.7.4. Value Creation Analysis
14.4.6.8. AZD6738 (AstraZeneca)
14.4.6.8.1. Target Patient Population
14.4.6.8.2. Sales Forecast (USD Million)
14.4.6.8.3. Net Present Value (USD Million)
14.4.6.8.4. Value Creation Analysis
14.4.6.9. APX3330 (Apexian Pharmaceuticals)
14.4.6.9.1. Target Patient Population
14.4.6.9.2. Sales Forecast (USD Million)
14.4.6.9.3. Net Present Value (USD Million)
14.4.6.9.4. Value Creation Analysis
14.4.6.10. CB-839 (Calithera Biosciences)
14.4.6.10.1. Target Patient Population
14.4.6.10.2. Sales Forecast (USD Million)
14.4.6.10.3. Net Present Value (USD Million)
14.4.6.10.4. Value Creation Analysis
14.4.6.11. CX-5461 (Senhwa Biosciences)
14.4.6.11.1. Target Patient Population
14.4.6.11.2. Sales Forecast (USD Million)
14.4.6.11.3. Net Present Value (USD Million)
14.4.6.11.4. Value Creation Analysis
14.4.6.12. LB-100 (Lixte Biotechnology)
14.4.6.12.1. Target Patient Population
14.4.6.12.2. Sales Forecast (USD Million)
14.4.6.12.3. Net Present Value (USD Million)
14.4.6.12.4. Value Creation Analysis
14.4.6.13. SRA737-01 (Sierra Oncology)
14.4.6.13.1. Target Patient Population
14.4.6.13.2. Sales Forecast (USD Million)
14.4.6.13.3. Net Present Value (USD Million)
14.4.6.13.4. Value Creation Analysis
14.4.6.14. SRA737-02 (Sierra Oncology)
14.4.6.14.1. Target Patient Population
14.4.6.14.2. Sales Forecast (USD Million)
14.4.6.14.3. Net Present Value (USD Million)
14.4.6.14.4. Value Creation Analysis
14.4.7. Concluding Remarks

15 CONCLUDING REMARKS

16 EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Artios Pharma
16.2.1. Company / Organization Snapshot
16.2.2. Interview Transcript: Simon Boulton, Vice President, Science Strategy
16.3. IMPACT Therapeutics
16.3.1. Company / Organization Snapshot
16.3.2. Interview Transcript: Yi Xu, Associate Director
16.4. Harvard Medical School
16.4.1. Company / Organization Snapshot
16.4.2. Interview Transcript: Norbert Perrimon, Professor, Department of Genetics
16.5. Panjab University
16.5.1. Company / Organization Snapshot
16.5.2. Interview Transcript: Vivek Dharwal, Professor, Department of Biochemistry
16.6. UbiQ
16.6.1. Company / Organization Snapshot
16.6.2. Interview Transcript: Alfred Nijkerk, Chief Executive Officer

17 APPENDIX 1: TABULATED DATA

18 APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures
Figure 3.1 Types of DNA Damage
Figure 3.2 Types of DNA Damaging Agents
Figure 3.3 DNA Damage and Repair Systems
Figure 3.4 DNA Damage Response Systems
Figure 3.5 Steps Involved in Base Excision Repair Pathway
Figure 3.6 Steps Involved in Nucleotide Excision Repair Pathway
Figure 3.7 Steps Involved in Mismatch Repair Pathway
Figure 3.8 Steps Involved in Homologous Recombination Repair Pathway
Figure 3.9 Steps Involved in Non-Homologous Repair Pathway
Figure 3.10 Genetic Disorders Caused due to Defects in DNA Repair Pathways
Figure 4.1 Historical Evolution of Synthetic Lethality
Figure 4.2 Synthetic Lethality in Other Cellular Pathways
Figure 4.3 Applications of Synthetic Lethality
Figure 4.4 Limitations of Synthetic Lethality
Figure 4.5 Screening Platforms for Synlet Target Identification
Figure 4.6 Recent News on Google: Emerging Focus Areas
Figure 4.7 Google Trend Analysis: Historical Timeline
Figure 4.8 Google Trends Analysis: Geographical Activity
Figure 4.9 Google Trends Analysis: Co-Relation with Other Therapeutic Areas
Figure 5.1 Synthetic Lethality-based Drugs: Distribution by Phase of Development
Figure 5.2 Synthetic Lethality-based Drugs: Distribution by Type of Molecule
Figure 5.3 Synthetic Lethality-based Drugs: Distribution by Type of Therapy
Figure 5.4 Synthetic Lethality-based Drugs: Distribution by Synlet Target
Figure 5.5 Synthetic Lethality-based Drugs: Distribution by Type of Patient Segment
Figure 5.6 Synthetic Lethality-based Drugs: Distribution by Therapeutic Area
Figure 5.7 Synthetic Lethality-based Drugs: Distribution by Target Indication
Figure 5.8 Synthetic Lethality-based Drugs: Distribution by Route of Administration
Figure 5.9 Synthetic Lethality-based Drug Developers: Distribution by Year of Establishment
Figure 5.10 Synthetic Lethality-based Drug Developers: Distribution by Location of Headquarters
Figure 5.11 Synthetic Lethality-based Drug Developers: Distribution by Company Size
Figure 5.12 Synthetic Lethality Drug-based Developers: Distribution by Company Size and Location of Headquarters
Figure 7.1 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets, January 2010-May 2019
Figure 7.2 Social Media Analysis: Historical Trends on Twitter, 2010-2019
Figure 7.3 Social Media Analysis: Evolutionary Trends on Twitter, 2010-2019
Figure 7.4 Social Media Analysis: Trending Words / Phrases on Twitter
Figure 7.5 Social Media Analysis: Most Prolific Contributors on Twitter
Figure 7.6 Social Media Analysis: Most Popular Synlet Targets / Patient Mutations on Twitter
Figure 7.7 Social Media Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
Figure 7.8 Social Media Analysis: Most Popular Indications on Twitter
Figure 7.9 Social Media Analysis: Year-Wise Trend in Activity for Popular Target Indications
Figure 7.10 Social Media Analysis: Distribution by Synlet Target and Target Indication
Figure 7.11 Social Media Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations and Target Indications
Figure 8.1 Publication Analysis: Distribution by Type of Publication
Figure 8.2 Publication Analysis: Distribution by Study Objective
Figure 8.3 Publication Analysis: Cumulative Year-wise Trend, 2017-2019
Figure 8.4 Publication Analysis: Emerging Focus Areas
Figure 8.5 Publication Analysis: Most Popular Synlet Targets / Patient Mutations
Figure 8.6 Publication Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
Figure 8.7 Publication Analysis: Most Popular Target Indications
Figure 8.8 Publication Analysis: Year-Wise Trend in Activity for Popular Target Indications
Figure 8.9 Publications Analysis: Key Journals Based on Number of Publications
Figure 8.10 Publications Analysis: Distribution by Journal Impact Factor
Figure 8.11 Publications Analysis: Key Journals Based on Journal Impact Factor
Figure 8.12 Publications Analysis: Key Research Hubs
Figure 8.13 Publications Analysis: Most Popular Authors
Figure 8.14 Publication Analysis: Most Popular Grant Bodies
Figure 8.15 Publication Analysis: Location of Grant Bodies
Figure 8.16 Publication Analysis: Multivariate Publication Benchmark Analysis
Figure 9.1 Abstract Analysis: Cumulative Year-wise Trend, 2013-2019
Figure 9.2 Abstract Analysis: Emerging Focus Areas
Figure 9.3 Abstract Analysis: Most Popular Drugs
Figure 9.4 Abstract Analysis: Most Popular Synlet Targets / Patient Mutations
Figure 9.5 Abstract Analysis: Most Popular Target Indications
Figure 9.6 Abstract Analysis: Regional Distribution of Principal Authors
Figure 9.7 Abstract Analysis: Industry Type of Principal Authors
Figure 9.8 Abstract Analysis: Most Active Organizations
Figure 9.9 Abstract Analysis: Distribution by Author Designation
Figure 9.10 Abstract Analysis: Most Popular Authors
Figure 10.1 Grant Analysis: Cumulative Trend by Year of Award, 2014-2019
Figure 10.2 Grant Analysis: Cumulative Trend by Amount Awarded (USD Million), 2014-2019
Figure 10.3 Grant Analysis: Distribution by Administering Institute Center
Figure 10.4 Grant Analysis: Distribution by Funding Institute Center
Figure 10.5 Grant Analysis: Distribution by Support Period
Figure 10.6 Grant Analysis: Distribution by Funding Institute Center and Support Period
Figure 10.7 Grant Analysis: Most Popular NIH Funding Categorization
Figure 10.8 Grant Analysis: Analysis by Funding Mechanism
Figure 10.9 Grant Analysis: Analysis by Emerging Focus Areas
Figure 10.10 Grant Analysis: Most Popular Synlet Targets / Patient Mutations
Figure 10.11 Grant Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
Figure 10.12 Grant Analysis: Most Popular Target Indications
Figure 10.13 Grant Analysis: Year-Wise Trend in Activity for Popular Target Indications
Figure 10.14 Grant Analysis: Distribution by Type of Grant Application
Figure 10.15 Grant Analysis: Most Popular NIH Departments
Figure 10.16 Grant Analysis: Distribution by Study Section
Figure 10.17 Grant Analysis: Type of Recipient Organization
Figure 10.18 Grant Analysis: Most Popular Recipient Organization
Figure 10.19 Grant Analysis: Most Popular Recipient Organizations and NIH Spending Sectors
Figure 10.20 Grant Analysis: Distribution by Grant Activity
Figure 10.21 Grant Analysis: Most Prominent Project Leaders
Figure 10.22 Grant Analysis: Regional Distribution of Recipient Organization
Figure 10.23 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Figure 10.24 Grant Analysis: Multivariate Grant Attractiveness Analysis
Figure 11.1 Distribution by Type of Funding and Year of Establishment, 2010-2019
Figure 11.2 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding and Year, 2010-2019
Figure 11.4 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2019
Figure 11.5 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Figure 11.6 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019
Figure 11.7 Funding and Investment Analysis: Summary of Investments, 2010-2019 (USD Million)
Figure 11.8 Funding and Investment Analysis: Distribution by Type of Company
Figure 11.9 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Company
Figure 11.10 Funding and Investment Analysis: Distribution by Purpose of Funding
Figure 11.11 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding
Figure 11.12 Funding and Investment Analysis: Distribution by Type of Molecule
Figure 11.13 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule
Figure 11.14 Funding and Investment Analysis: Distribution by Synlet Target
Figure 11.15 Funding and Investment Analysis: Distribution of the Total Amount Invested by Synlet Target
Figure 11.16 Funding and Investment Analysis: Distribution by Therapeutic Area
Figure 11.17 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area
Figure 11.18 Funding and Investment Analysis: Distribution by Target Indication
Figure 11.19 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication
Figure 11.20 Funding and Investment Analysis: Distribution by Geography
Figure 11.21 Funding and Investment Analysis: Most Active Players by Number of Instances
Figure 11.22 Funding and Investment Analysis: Most Active Investors by Amount Invested (USD Million)
Figure 11.23 Funding and Investment Summary, 2010-2019 (USD Million)
Figure 12.1 Target Benchmark Analysis: Clinically Validated Synlet Targets
Figure 12.2 Target Benchmark Analysis: Preclinically Validated Synlet Targets
Figure 12.3 Target Benchmark Analysis: Early Stage Research Validated Synlet Targets
Figure 13.1 Companion Diagnostics: Role in Clinical Trials
Figure 13.2 Advantages of Companion Diagnostics
Figure 13.3 Companion Diagnostics: Distribution by Synlet Target
Figure 13.4 Companion Diagnostics: Distribution by Type of Biomarker
Figure 13.5 Companion Diagnostics: Distribution by Type of Biomarker and Technology
Figure 13.6 Companion Diagnostics: Distribution by Target Indication
Figure 13.7 Companion Diagnostics: Distribution by Developer and Synlet Target
Figure 13.8 Companion Diagnostics: Most Prominent Developers
Figure 13.9 Working Process of myChoice® HRD CDx
Figure 13.10 Approval Timeline of BRACAnalysis CDx® for Olaparib
Figure 13.11 Working Process of BRACAnalysis CDx®Diagnostics Kit
Figure 13.12 Companion Diagnostics Tests for Rucaparib
Figure 13.13 Companion Diagnostics in Drug Development: Market Drivers and Restraints
Figure 14.1 Synthetic Lethality-based Drugs Market: Forecast Methodology and Key Assumptions
Figure 14.2 Overall Synthetic Lethality-based Drugs Market, 2019-2030
Figure 14.3 Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030
Figure 14.4 Synthetic Lethality-based Drugs Market for Small Molecules, 2019-2030 (USD Million)
Figure 14.5 Synthetic Lethality-based Drugs Market for Biologics, 2019-2030 (USD Million)
Figure 14.6 Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030
Figure 14.7 Synthetic Lethality-based Drugs Market for APE1 / Ref-1, 2019-2030 (USD Million)
Figure 14.8 Synthetic Lethality-based Drugs Market for Chk, 2019-2030 (USD Million)
Figure 14.9 Synthetic Lethality-based Drugs Market for GLS1, 2019-2030 (USD Million)
Figure 14.10 Synthetic Lethality-based Drugs Market for PARP, 2019-2030 (USD Million)
Figure 14.11 Synthetic Lethality-based Drugs Market for Pol θ, 2019-2030 (USD Million)
Figure 14.12 Synthetic Lethality-based Drugs Market for PP2A, 2019-2030 (USD Million)
Figure 14.13 Synthetic Lethality-based Drugs Market for Wee1, 2019-2030 (USD Million)
Figure 14.14 Synthetic Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030
Figure 14.15 Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030 (USD Million)
Figure 14.16 Synthetic Lethality-based Drugs Market for Colorectal Cancer, 2019-2030 (USD Million)
Figure 14.17 Synthetic Lethality-based Drugs Market for Fallopian Tube Cancer, 2019-2030 (USD Million)
Figure 14.18 Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030 (USD Million)
Figure 14.19 Synthetic Lethality-based Drugs Market for Head and Neck Cancer, 2019-2030 (USD Million)
Figure 14.20 Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030 (USD Million)
Figure 14.21 Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030 (USD Million)
Figure 14.22 Synthetic Lethality-based Drugs Market for Peritoneal Cancer, 2019-2030 (USD Million)
Figure 14.23 Synthetic Lethality-based Drugs Market for Others, 2019-2030 (USD Million)
Figure 14.24 Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019 and 2030
Figure 14.25 Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030
Figure 14.26 Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030
Figure 14.27 Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030
Figure 14.28 Synthetic Lethality-based Drugs Market in the US, 2019-2030
Figure 14.29 Synthetic Lethality-based Drugs Market in France, 2019-2030
Figure 14.30 Synthetic Lethality-based Drugs Market in Germany, 2019-2030
Figure 14.31 Synthetic Lethality-based Drugs Market in Italy, 2019-2030
Figure 14.32 Synthetic Lethality-based Drugs Market in Spain, 2019-2030
Figure 14.33 Synthetic Lethality-based Drugs Market in the UK, 2019-2030
Figure 14.34 Synthetic Lethality-based Drugs Market in Australia, 2019-2030
Figure 14.35 Synthetic Lethality-based Drugs Market in China, 2019-2030
Figure 14.36 Synthetic Lethality-based Drugs Market in Japan, 2019-2030
Figure 14.37 Niraparib (GlaxoSmithKline): Current Status of Development
Figure 14.38 Niraparib (GlaxoSmithKline): Sales Forecast, till 2030 (USD Million)
Figure 14.39 Olaparib (AstraZeneca): Current Status of Development
Figure 14.40 Olaparib (AstraZeneca): Sales Forecast, till 2030 (USD Million)
Figure 14.41 Rucaparib (Clovis Oncology): Current Status of Development
Figure 14.42 Rucaparib (Clovis Oncology): Sales Forecast, till 2030 (USD Million)
Figure 14.43 Talazoparib (Pfizer): Current Status of Development
Figure 14.44 Talazoparib (Pfizer): Sales Forecast, till 2030 (USD Million)
Figure 14.45 Pamiparib (BeiGene): Current Status of Development
Figure 14.46 Pamiparib (BeiGene): Sales Forecast, till 2030 (USD Million)
Figure 14.47 Veliparib (AbbVie): Current Status of Development
Figure 14.48 Veliparib (AbbVie): Sales Forecast, till 2030 (USD Million)
Figure 14.49 Adavosertib (AstraZeneca): Current Status of Development
Figure 14.50 Adavosertib (AstraZeneca): Sales Forecast, till 2030 (USD Million)
Figure 14.51 AZD6738 (AstraZeneca): Current Status of Development
Figure 14.52 AZD6738 (AstraZeneca): Sales Forecast, till 2030 (USD Million)
Figure 14.53 APX3330 (Apexian Pharmaceuticals): Current Status of Development
Figure 14.54 APX3330 (Apexian Pharmaceuticals): Sales Forecast, till 2030 (USD Million)
Figure 14.55 CB-839 (Calithera Biosciences): Current Status of Development
Figure 14.56 CB-839 (Calithera Biosciences): Sales Forecast, till 2030 (USD Million)
Figure 14.57 CX-5461 (Senhwa Biosciences): Current Status of Development
Figure 14.58 CX-5461 (Senhwa Biosciences): Sales Forecast, till 2030 (USD Million)
Figure 14.59 LB-100 (Lixte Biotechnology): Current Status of Development
Figure 14.60 LB-100 (Lixte Biotechnology): Sales Forecast, till 2030 (USD Million)
Figure 14.61 SRA737-01 (Sierra Oncology): Current Status of Development
Figure 14.62 SRA737-01 (Sierra Oncology): Sales Forecast, till 2030 (USD Million)
Figure 14.63 SRA737-02 (Sierra Oncology): Current Status of Development
Figure 14.64 SRA737-02 (Sierra Oncology): Sales Forecast, till 2030 (USD Million)
Figure 14.65 Overall Synthetic Lethality-based Drugs Market, 2019, 2025 and 2030, Base, Optimistic and Conservative Scenario (USD Million)

List of Tables
Table 3.1 Key Components of DNA Repair Systems
Table 3.2 Difference between HRR and Non-Homologous End Joining Pathway
Table 3.3 DNA Damage Repair Related Inheritable Mutations
Table 5.1 Synthetic Lethality-based Drugs: Marketed and Development Pipeline
Table 5.2 Synthetic Lethality-based Drugs: Information on Target Indications
Table 5.3 Synthetic Lethality-based Drugs: List of Drug Developers
Table 6.1 AbbVie: Key Highlights
Table 6.2 Drug Profile: Veliparib (ABT-888)
Table 6.3 AbbVie: Recent Developments and Future Outlook
Table 6.4 AstraZeneca: Key Highlights
Table 6.5 Drug Profile: Olaparib (ABT-888)
Table 6.6 Drug Profile: AZD6738
Table 6.7 Drug Profile: AZD1775
Table 6.8 AstraZeneca: Recent Developments and Future Outlook
Table 6.9 BeiGene: Key Highlights
Table 6.10 Drug Profile: Pamiparib (BGB-290)
Table 6.11 BeiGene: Recent Developments and Future Outlook
Table 6.12 Clovis Oncology: Key Highlights
Table 6.13 Drug Profile: Rucaparib (Rubraca®)
Table 6.14 Clovis Oncology: Recent Developments and Future Outlook
Table 6.15 GlaxoSmithKline: Key Highlights
Table 6.16 Drug Profile: Niraparib (Zejula®)
Table 6.17 GlaxoSmithKline: Recent Developments and Future Outlook
Table 6.18 Pfizer: Key Highlights
Table 6.19 Drug Profile: Talazoparib (BMN 673)
Table 6.20 Pfizer: Recent Developments and Future Outlook
Table 6.21 AtlasMedx: Key Highlights
Table 6.22 Chordia Therapeutics: Key Highlights
Table 6.23 IDEAYA Biosciences: Key Highlights
Table 6.24 Mission Therapeutics: Key Highlights
Table 6.25 Repare Therapeutics: Key Highlights
Table 6.26 Sierra Oncology: Key Highlights
Table 6.27 SyntheX Labs: Key Highlights
Table 8.1 Publication Analysis: Details on Popular Authors
Table 8.2 Synthetic Lethality: List of Recent Publications, 2019
Table 8.3 Publication Analysis: List of Most Valued Publications
Table 9.1 Abstract Analysis: List of ASCO Abstracts, 2013-2019
Table 9.2 Abstract Analysis: Details on Principal Authors
Table 10.1 Grant Analysis: List of Most Attractive Grants
Table 12.1 List of Clinically Validated Synlet Targets
Table 12.2 List of Preclinically Validated Synlet Targets
Table 12.3 List of Early Stage Research Oriented Synlet Targets
Table 12.4 List of Big Pharmaceutical Players and Respective Synlet Targets
Table 13.1 Companion Diagnostics: List of Available / Under Development Tests
Table 13.2 Companion Diagnostics for Synlet Targets: Information on Drug, Indication, Device Type and Sample Used
Table 13.3 Companion Diagnostics: Potential Partnership Opportunities
Table 14.1. Synthetic Lethality-based Drugs: Promising Drug Candidates
Table 14.2. Synthetic Lethality Market: Value Creation Analysis
Table 16.1 Artios Pharma: Company / Organization Snapshot
Table 16.2 IMPACT Therapeutics: Company / Organization Snapshot
Table 16.3 Harvard Medical School: Company / Organization Snapshot
Table 16.4 Panjab University: Company / Organization Snapshot
Table 16.5 UbiQ: Company / Organization Snapshot
Table 17.1 Google Trend Analysis: Historical Timeline
Table 17.2 Google Trends Analysis: Geographical Activity
Table 17.3 Google Trends Analysis: Co-Relation with Other Therapeutic Areas
Table 17.4 Synthetic Lethality-based Drugs: Distribution by Phase of Development
Table 17.5 Synthetic Lethality-based Drugs: Distribution by Type of Molecule
Table 17.6 Synthetic Lethality-based Drugs: Distribution by Type of Therapy
Table 17.7 Synthetic Lethality-based Drugs: Distribution by Type of Synlet Target
Table 17.8 Synthetic Lethality-based Drugs: Distribution by Type of Patient Segment
Table 17.9 Synthetic Lethality-based Drugs: Distribution by Therapeutic Area
Table 17.10 Synthetic Lethality-based Drugs: Distribution by Target Indication
Table 17.11 Synthetic Lethality-based Drugs: Distribution by Route of Administration
Table 17.12 Synthetic Lethality-based Drug Developers: Distribution by Year of Establishment
Table 17.13 Synthetic Lethality-based Drug Developers: Distribution by Location of Headquarters
Table 17.14 Synthetic Lethality-based Drug Developers: Distribution by Company Size
Table 17.15 Synthetic Lethality-based Drug Developers: Distribution by Company Size and Location of Headquarters
Table 17.16 Social Media Analysis: Cumulative Year-Wise Activity by Volume of Tweets, January 2010- May 2019
Table 17.17 Social Media Analysis: Historical Trends on Twitter, 2010-2019
Table 17.18 Social Media Analysis: Most Prolific Contributors on Twitter
Table 17.19 Social Media Analysis: Most Popular Synlet Targets / Patient Mutations on Twitter
Table 17.20 Social Media Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
Table 17.21 Social Media Analysis: Most Popular Indications on Twitter
Table 17.22 Social Media Analysis: Year-Wise Trend in Activity for Popular Synthetic Target Indications
Table 17.23 Social Media Analysis: Distribution by Synlet Target and Target Indication
Table 17.24 Social Media Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations and Indications
Table 17.25 Publication Analysis: Distribution by Type of Publication
Table 17.26 Publication Analysis: Distribution by Study Objective
Table 17.27 Publication Analysis: Cumulative Year-wise Trend, 2017-2019
Table 17.28 Publication Analysis: Most Popular Synlet Targets
Table 17.29 Publication Analysis: Year-Wise Trend for Most Popular Synlet Targets / Patient Mutations
Table 17.30 Publication Analysis: Most Popular Target Indications
Table 17.31 Publication Analysis: Year-Wise Trend for Most Popular Target Indications
Table 17.32 Publication Analysis: Key Journals Based on Number of Publications
Table 17.33 Publication Analysis: Distribution by Journal Impact Factor
Table 17.34 Publication Analysis: Key Journals Based on Journal Impact Factor
Table 17.35 Publication Analysis: Key Research Hubs
Table 17.36 Publication Analysis: Most Popular Authors
Table 17.37 Publication Analysis: Most Popular Grant Bodies
Table 17.38 Publication Analysis: Location of Grant Bodies
Table 17.39 Publication Analysis: Multivariate Publication Benchmark Analysis
Table 17.40 Abstract Analysis: Cumulative Year-wise Trend, 2013-2019
Table 17.41 Abstract Analysis: Most Popular Drugs
Table 17.42 Abstract Analysis: Most Popular Synlet Targets / Patient Mutations
Table 17.43 Abstract Analysis: Most Popular Target Indications
Table 17.44 Abstract Analysis: Regional Distribution of Principal Authors
Table 17.45 Abstract Analysis: Industry Type of Principal Authors
Table 17.46 Abstract Analysis: Most Active Organizations
Table 17.47 Abstract Analysis: Distribution by Author Designation
Table 17.48 Abstract Analysis: Most Popular Authors
Table 17.49 Grant Analysis: Cumulative Trend by Year of Award, 2014-2019
Table 17.50 Grant Analysis: Cumulative Trend by Amount Awarded (USD Million), 2014- 2019
Table 17.51 Grant Analysis: Distribution by Administering Institute Center
Table 17.52 Grant Analysis: Distribution by Funding Institute Center
Table 17.53 Grant Analysis: Distribution by Support Period
Table 17.54 Grant Analysis: Distribution by Funding Institute Center and Support Period
Table 17.55 Grant Analysis: Most Popular NIH Funding Categorization
Table 17.56 Grant Analysis: Analysis by Funding Mechanism
Table 17.57 Grant Analysis: Most Popular Synlet Targets / Patient Mutations
Table 17.58 Grant Analysis: Year-Wise Trend in Activity for Popular Synlet Targets / Patient Mutations
Table 17.59 Grant Analysis: Popular Target Indications
Table 17.60 Grant Analysis: Year-Wise Trend in Activity for Popular Target Indications
Table 17.61 Grant Analysis: Distribution by Type of Grant Application
Table 17.62 Grant Analysis: Most Popular NIH Departments
Table 17.63 Grant Analysis: Distribution by Study Section
Table 17.64 Grant Analysis: Type of Recipient Organization
Table 17.65 Grant Analysis: Most Popular Recipient Organization
Table 17.66 Grant Analysis: Most Popular Recipient Organizations and NIH Spending Sectors
Table 17.67 Grant Analysis: Distribution by Grant Activity
Table 17.68 Grant Analysis: Most Prominent Project Leaders
Table 17.69 Grant Analysis: Regional Distribution of Recipient Organization
Table 17.70 Grant Analysis: Categorizations based on Weighted Attractiveness Scores
Table 17.71 Grant Analysis: Multivariate Grant Attractiveness Analysis
Table 17.72 Distribution by Type of Funding and Year of Establishment, 2010-2019
Table 17.73 Funding and Investment Analysis: Cumulative Number of Instances by Year, 2010-2019
Table 17.74 Funding and Investment Analysis: Distribution by Type of Funding and Year, 2010-2019
Table 17.75 Funding and Investment Analysis: Cumulative Amount Invested, 2010-2019
Table 17.76 Funding and Investment Analysis: Distribution of Instances by Type of Funding, 2010-2019
Table 17.77 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Funding, 2010-2019
Table 17.78 Funding and Investment Analysis: Summary of Investments, 2010-2019 (USD Million)
Table 17.79 Funding and Investment Analysis: Distribution by Type of Company
Table 17.80 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Company
Table 17.81 Funding and Investment Analysis: Distribution by Purpose of Funding
Table 17.82 Funding and Investment Analysis: Distribution of the Total Amount Invested by Purpose of Funding
Table 17.83 Funding and Investment Analysis: Distribution by Type of Molecule
Table 17.84 Funding and Investment Analysis: Distribution of the Total Amount Invested by Type of Molecule
Table 17.85 Funding and Investment Analysis: Distribution by Synlet Target
Table 17.86 Funding and Investment Analysis: Distribution of the Total Amount Invested by Synlet Target
Table 17.87 Funding and Investment Analysis: Distribution by Therapeutic Area
Table 17.88 Funding and Investment Analysis: Distribution of the Total Amount Invested by Therapeutic Area
Table 17.89 Funding and Investment Analysis: Distribution by Target Indication
Table 17.90 Funding and Investment Analysis: Distribution of the Total Amount Invested by Target Indication
Table 17.91 Funding and Investment Analysis: Distribution by Geography
Table 17.92 Funding and Investment Analysis: Most Active Players by Number of Instances
Table 17.93 Funding and Investment Analysis: Most Active Investors by Amount Invested (USD Million)
Table 17.94 Funding and Investment Summary, 2010-2019 (USD Million)
Table 17.95 Companion Diagnostics: Distribution by Synlet Target
Table 17.96 Companion Diagnostics: Distribution by Type of Biomarker
Table 17.97 Companion Diagnostics: Distribution by Type of Biomarker and Technology
Table 17.98 Companion Diagnostics: Distribution by Target Indication
Table 17.99 Companion Diagnostics: Distribution by Developer and Synlet Target
Table 17.100 Companion Diagnostics: Most Prominent Developers
Table 17.101 Overall Synthetic Lethality-based Drugs Market, 2019-2030
Table 17.102 Synthetic Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030
Table 17.103 Synthetic Lethality-based Drugs Market for Small Molecule, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.104 Synthetic Lethality-based Drugs Market for Biologic, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.105 Synthetic Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030
Table 17.106 Synthetic Lethality-based Drugs Market for APE1 / Ref-1, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.107 Synthetic Lethality-based Drugs Market for Chk, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.108 Synthetic Lethality-based Drugs Market for GLS1, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.109 Synthetic Lethality-based Drugs Market for PARP, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.110 Synthetic Lethality-based Drugs Market for Pol θ, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.111 Synthetic Lethality-based Drugs Market for PP2A, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.112 Synthetic Lethality-based Drugs Market for Wee1, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.113 Synthetic Lethality-based Drugs Market: Distribution by Target Indications, 2019 and 2030
Table 17.114 Synthetic Lethality-based Drugs Market for Breast Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.115 Synthetic Lethality-based Drugs Market for Colorectal Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.116 Synthetic Lethality-based Drugs Market for Fallopian Tube Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.117 Synthetic Lethality-based Drugs Market for Gastric Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.118 Synthetic Lethality-based Drugs Market for Head and Neck Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.119 Synthetic Lethality-based Drugs Market for Lung Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.120 Synthetic Lethality-based Drugs Market for Ovarian Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.121 Synthetic Lethality-based Drugs Market for Peritoneal Cancer, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.122 Synthetic Lethality-based Drugs Market for Others, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.123 Synthetic Lethality-based Drugs Market: Distribution by Route of Administration, 2019 and 2030
Table 17.124 Synthetic Lethality-based Drugs Market for Oral Therapies, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.125 Synthetic Lethality-based Drugs Market for Intravenous Therapies, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.126 Synthetic Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030
Table 17.127 Synthetic Lethality-based Drugs Market in the US, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.128 Synthetic Lethality-based Drugs Market in France, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.129 Synthetic Lethality-based Drugs Market in Germany, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.130 Synthetic Lethality-based Drugs Market in Italy, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.131 Synthetic Lethality-based Drugs Market in Spain, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.132 Synthetic Lethality-based Drugs Market in the UK, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.133 Synthetic Lethality-based Drugs Market in Australia, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.134 Synthetic Lethality-based Drugs Market in China, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.135 Synthetic Lethality-based Drugs Market in Japan, 2019-2030: Base, Optimistic, Conservative Case (USD Million)
Table 17.136 Niraparib (GlaxoSmithKline): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.137 Olaparib (AstraZeneca): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.138 Rucaparib (Clovis Oncology): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.139 Talazoparib (Pfizer): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.140 Pamiparib (BeiGene): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.141 Veliparib (AbbVie): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.142 Adavosertib (AstraZeneca): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.143 AZD6738 (AstraZeneca): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.144 APX3330 (Apexian Pharmaceuticals): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.145 CB-839 (Calithera Biosciences): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.146 CX-5461 (Senhwa Biosciences): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.147 LB-100 (Lixte Biotechnology): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.148 SRA737-01 (Sierra Oncology): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.149 SRA737-02 (Sierra Oncology): Sales Forecast, till 2030, Base, Optimistic, Conservative Case (USD Million)
Table 17.150 Overall Synthetic Lethality-based Drugs Market, 2019, 2025 and 2030: Base, Optimistic and Conservative Scenario (USD Million)

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3W Partners
  • BioMedical Catalyst Fund
  • European Research Council
  • Lilly Asia Ventures
  • Pharmacyclics
  • SyntheX Labs
  • MORE

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the current state of the synthetic lethality-based drugs market and its likely evolution in the short-mid term and long term.

Chapter 3 provides a general introduction to the DNA damage and associated repair systems in the human body. This section features a detailed discussion on the different types of DNA damage that have been identified so face, along with their respective causes. It also features detailed descriptions of DNA repair systems and associated biological pathways that are activated during the detection of damage within the cell’s genetic code. Further, the chapter includes a discussion on the potential therapeutic benefits of targeting defects in DNA repair pathways for the treatment of different disease indications, such as cancer.

Chapter 4 provides an overview of the concept of synthetic lethality, including details on the associated pathways and their respective mechanisms of action. Further, it includes a discussion on the conception, historical evolution, importance, applications and challenges related to the use of synthetic lethality as a therapeutic principle. The chapter also highlights the most popular types of screening approaches that are used in the identification of synlet gene pairs. Additionally, it includes an analysis of contemporary Google Trends (as of June 2019) and insights from recent news articles related to the concept of synthetic lethality.
 
Chapter 5 includes information on nearly 75 synthetic lethality-based drugs that are currently approved or under development for the treatment of various indications. It features a comprehensive analysis of pipeline molecules, highlighting phase of development (marketed, clinical, preclinical and discovery stage) of lead candidates, type of molecule (small molecule and biologic), type of therapy (monotherapy and combination therapy), type of synlet target, target patient segment, key therapeutic area(s) and target indication(s), and route of administration of the drugs that are being developed for the treatment of cancer. Further, the chapter provides information on drug developer(s), highlighting their year of establishment, location of headquarters and employee strength. In addition, the chapter highlights the various screening platforms that are being actively used by the industry to study synlet interactions between gene pairs.

Chapter 6 features detailed profiles of some of the large companies developing synthetic lethality-based drugs (shortlisted on the basis of phase of development of pipeline products). Each company profile includes a brief overview of the company, its financial information (if available), detailed descriptions of their synthetic lethality-based drugs, and a comprehensive future outlook. Additionally, each drug profile features information on type of drug, route of administration, indications, current status of development and an excerpt on its developmental history. In addition, the chapter includes tabulated profiles of small-sized and mid-sized players (shortlisted on the basis of the number of pipeline products), featuring details on the innovator company (such as location of headquarters, year of establishment, number of employees, and key members of executive team,) recent developments, along with  descriptions of their synthetic lethality-based drug candidates.

Chapter 7 provides insights on the popularity of synthetic lethality on the social media platform, Twitter. The section highlights the yearly distribution of tweets, posted on the platform during the period 2010-2019 (till May), and the most significant events responsible for increase in the volume of tweets each year. Additionally, the chapter highlights the most prolific contributors, frequently discussed synlet targets, popular disease indications, and a multivariate tweet benchmark analysis in order to highlight the most popular tweets.

Chapter 8 provides a detailed analysis of close to 700 peer-reviewed scientific articles related to synthetic lethality, published during the period 2017-2019 (till May). The analysis takes into consideration target disease indications, synlet targets, and analysis based on various relevant parameters, such as study type (review article, research article and case report), research objective, year of publication, key research hubs, most popular authors, provision of grant support, and most popular journals (in terms of number of articles published in the given time period and journal impact factor). The chapter also features detailed valuation analysis for recent publications.

Chapter 9 features a detailed analysis of various abstracts  related to synthetic lethality presented at ASCO in the period 2013-2019 (till May). The analysis is based on multiple parameters, such as year of (abstract) publication, popular drugs, synlet targets, target cancer indications, popular authors, author designations, industry type (industry and academia) and most active organizations (in terms of published abstracts). In addition, this chapter features a multi-dimensional bubble chart analysis to assess the relative level of expertise of the key authors / researchers based on number of publications, citation count and research gate score.

Chapter 10 provides information on close to 750 grants that were awarded to research institutes engaged in projects related to synthetic lethality, between 2014 and 2019 (till May). The analysis also highlights important parameters associated with grants, such as year of award, support period, amount awarded, funding institute, administration institute center, funding institute center, funding mechanism, spending categorization, grant type, responsible study section, focus area, type of recipient organization and prominent program officers. It also features a detailed analysis on most popular targets and target indications, along with a multivariate grant attractiveness analysis based on parameters; such as amount awarded, support period, grant type, number of synlet targets and number of indications under study.

Chapter 11 presents details on various investments received by start-ups / small-sized and mid-sized companies that are engaged in this domain. It also includes an analysis of the funding instances that have taken place in the market, in the period 2017-2019 (till May), highlighting the growing interest of the venture capital (VC) community and other strategic investors within this domain.

Chapter 12 presents benchmark analysis of over 230 synlet targets identified from various credible sources (research publications, government funding, clinical studies, recent news / tweets and abstracts presented in global conferences), highlighting targets that have already been validated in clinical studies, preclinical studies and early-stage research (cases where there is no lead (therapeutic) candidate being investigated). Further, it also highlights the long-term opportunities (for drug developers) associated with individual targets, based on their popularity across different portals.

Chapter 13 presents information on various companion diagnostics tests that are commercially available / being investigated for drugs that are designed to exploit the synthetic lethality mechanism. The chapter analyzes the innovative companion diagnostics on the basis of several parameters, such as the synlet target, drug candidate(s) being investigated, target biomarker(s), target disease indication(s) and assay technique used. It also includes case studies, highlighting those companion diagnostic tests that are available and are being used to evaluate the therapeutic efficiency of approved PARP inhibitors using the principle of synthetic lethality.

Chapter 14 features a detailed market forecast of the likely growth of synthetic lethality-based drugs till the year 2030. We have provided inputs on the likely distribution of the current and forecasted opportunity across type of molecules (small molecule and biologic), target indications (breast cancer, colorectal cancer, fallopian tube cancer, gastric cancer, head and neck cancer, lung cancer, ovarian cancer, peritoneal cancer and others), synlet targets (APE1 / Ref-1, Chk1, GLS1, PARP, Pol θ, PP2A and Wee1), different route of administration (oral and intravenous) and key geographical regions (North America, EU5, Asia-Pacific and Rest of the World). To account for future uncertainties associated with the growth of synthetic lethality-based drugs market and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

Chapter 15 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of synthetic lethality-based drugs market.

Chapter 16 is a collection of interview transcripts of discussions held with key stakeholders in this market. In this chapter, we have presented the details of interviews held with (in alphabetical order of company names) Simon Boulton (Vice President, Science Strategy, Artios Pharma), Yi Xu (Associate Director, Business Development, IMPACT Therapeutics), Norbert Perrimon (Professor, Department of Genetics, Harvard Medical School), Vivek Dharwal (Professor, Department of Biochemistry, Panjab University) and Alfred Nijkerk (Chief Executive Officer, UbiQ).

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which provides the list of companies and organizations mentioned in this report.

Note: Product cover images may vary from those shown
5 of 5
  • 3W Partners
  • 5AM Ventures
  • 6 Dimensions Capital
  • 8VC
  • Abbott
  • AbbVie
  • AbbVie Ventures
  • Abingworth
  • Adage Capital Partners
  • Adams Street Partners
  • Advanced Technology Ventures
  • Agilent Technologies
  • Agios Pharmaceuticals
  • Alaska Women's Cancer Care
  • Alexandria Real Estate
  • Alexandria Venture Investments
  • Alex's Lemonade Stand Foundation for Childhood Cancer
  • Allergan
  • Almac
  • Altitude Life Science Ventures
  • Amadeus Capital Partners
  • American Association for Cancer Research
  • Amherst Fund
  • Amoy Diagnostics
  • Andera Partners
  • Angel Investors
  • Apexian Pharmaceuticals
  • Apjohn Ventures Fund
  • Apollo Munich Health
  • Aptose Biosciences
  • ARCH Venture Partners
  • Arix Bioscience
  • Arkin Holdings
  • Artios Pharma
  • Astellas Ventures
  • AstraZeneca
  • AtlasMedx
  • Atrin Pharmaceuticals
  • Austrian Science Fund
  • AVICT
  • Baylor College of Medicine
  • BDC Capital’s Healthcare Venture Fund
  • Beckman Research Institute
  • BeiGene
  • Beth Israel Deaconess Medical Center
  • Biodesix
  • Biogenex Laboratories
  • BioMed Ventures
  • BioMedical Catalyst Fund
  • bioMérieux
  • Biotechnology and Biological Sciences Research Council
  • Boehringer Ingelheim Venture Fund
  • Boston College
  • Boxer Capital of the Tavistock Group
  • Boyu Capital
  • Breast Cancer Now
  • Brigham And Women'S Hospital
  • Broad Institute
  • BVF Partners
  • C4X Discovery
  • Calibr
  • Calico
  • Calithera Biosciences
  • Cambridge Enterprise
  • Canaan Partners
  • Canadian Cancer Society Research Institute
  • Candiolo Cancer Institute
  • Capital Midwest Fund
  • CareNet Group
  • Case Western Reserve University
  • Caxton Alternative Management
  • Cedars-Sinai Medical Center
  • Celgene
  • CellCentric
  • Cellecta
  • Cenova Ventures
  • China Investment & Development
  • China Summit Capital
  • Chordia Therapeutics
  • CITIC Private Equity Funds Management
  • City of Hope National Medical Center
  • Cleveland Clinic Lerner College of Medicine
  • Clovis Oncology
  • Cold Spring Harbor Laboratory
  • Columbia University
  • Columbia University Medical Center
  • Cornerstone Parkwalk Advisors
  • CRT Pioneer Fund
  • CStone Pharmaceuticals
  • Cyteir Therapeutics
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Decheng Capital
  • Delphi Ventures
  • Driehaus Capital
  • DROIA
  • Duksung Women's University
  • EdiGene
  • eFFECTOR Therapeutics
  • Elevate Ventures
  • Emory University
  • Epic Sciences
  • EpiCypher
  • European Research Council
  • Fast Track Initiative
  • Flagship Ventures
  • Fonds de solidarité FTQ
  • Forward Informatics
  • Foundation Medicine
  • Frazier Healthcare Ventures
  • Fred Hutchinson Cancer Research Center
  • Fresenius Kabi
  • Fund for Scientific and Technological Research
  • Georgetown University
  • GIC
  • Google Ventures
  • Grand Angels
  • Green Pine Capital Partners
  • Guangzhou YUEXIU Industrial Investment Fund
  • Guardant Health
  • Gurdon Institute
  • H&Q Asia Pacific
  • HAIBANG Ventures
  • Harvard Medical School
  • Harvard University
  • Hopen Life Science Ventures
  • Horizon Discovery
  • HuagaiCapital
  • IDEAYA Biosciences
  • Ignyta
  • IMPACT Therapeutics
  • Imperial Innovations
  • Indiana University
  • Indiana Univ-Purdue Univ At Indianapolis
  • IndieBio
  • Innovate Indiana Fund
  • Innovate UK
  • Institute of Cancer Research
  • Institute of Nano Science and Technology
  • IP Group
  • Israel Science Foundation
  • Italian Association for Cancer Research
  • JAFCO
  • Janus Capital Management
  • Japan Agency for Medical Research and Development
  • Japan Society for the Promotion of Science
  • Johns Hopkins University
  • Jonathan Milner
  • King Star Capital
  • Kyoto University Innovation Capital
  • Leica Biosystems
  • Life Sciences Partners
  • LifeNet Health
  • Lightstone
  • Lilly Asia Ventures
  • Lixte Biotechnology
  • LP. Joining Adage
  • LUNGevity Foundation
  • M Ventures
  • Management
  • Marie Curie Initial Training Network CodeAge project
  • Massachusetts General Hospital
  • Mayo Clinic
  • MD Anderson Cancer Center
  • Merck Ventures
  • Metabomed
  • MetaStat
  • Ministry of Economy and Competitiveness
  • Ministry of Education - Singapore
  • Mission Bay Capital
  • Mission Therapeutics
  • Mitsubishi UFJ Capital
  • Mizuho Capital
  • Moffitt Cancer Center
  • Morgan Noble
  • Morgenthaler Ventures
  • Morphic Therapeutics
  • MPM Capital
  • MS Ventures
  • Mylan
  • Myriad Genetics
  • National Agency for Science and Technology
  • National Cancer Institute
  • National Human Genome Research Institute
  • National Institutes of Health
  • National League Against Cancer
  • National Natural Science Foundation of China
  • National Research Foundation of Korea
  • Natural Science Foundation of Guangdong Province
  • Natural Sciences and Engineering Research Council of Canada
  • Nextech Invest
  • Nippon Venture Capital
  • Northeastern University
  • Novartis Venture Fund
  • Ofinnova Partners
  • Ohio State University
  • ONO Pharma
  • OrbiMed Advisors
  • Oregon Health & Science University
  • Oriza Seed Venture Capital
  • Osage University Partners
  • Panjab University
  • Pangaea Biotech
  • Perceptive Advisors
  • Personal Genome Diagnostics
  • Pfizer
  • Pfizer Ventures
  • Pharmacyclics
  • Phi Life Sciences
  • Philadelphia Center
  • PhoreMost
  • Pontifax Fund
  • Premier Pain and Spine
  • Providence Investment Company
  • Qameleon Therapeutics
  • QIAGEN
  • Qualifying Therapeutic Discovery Project Program
  • RA Capital Management
  • Rainbow Seed Fund
  • Repare Therapeutics
  • Resolution Bioscience
  • Roche
  • Roche Venture Fund
  • Russian Foundation for Basic Research
  • Sakarya University
  • Sanford Burnham Prebys Medical Discovery Institute
  • São Paulo State Foundation
  • SBI Investment
  • Scripps Research Institute
  • Sectoral Asset Management
  • Selvita
  • SEngine Precision Medicine
  • Senhwa Biosciences
  • Sequoia China
  • Shanks Lab
  • Sheba Medical Center
  • Shinsei Capital Partners
  • Sierra Oncology
  • SignalRx Pharmaceuticals
  • Silicon Valley Bank
  • Singapore Ministry of Education
  • Singapore sovereign wealth fund
  • Sloan-Kettering Inst Can Research
  • Sloan-Kettering Institute
  • SMBC Venture Capital
  • Snap Bio
  • Sofinnova Partners
  • SOSV
  • SR One
  • SRI International
  • St George Hospital
  • St. Jude Children's Research Hospital
  • Stanford University
  • Sungent Bioventure
  • SV Health Investors
  • SV Life Sciences
  • SyntheX Labs
  • Taikang Insurance Group
  • Takeda Venture Investments
  • Tango Therapeutics
  • Technion Research and Development Foundation
  • Temple University
  • Temple University of The Commonwealth
  • Teneobio
  • Terra Mafnum Capital Partners
  • TESARO
  • The Column Group
  • The Institute of Cancer Research
  • The Ohio State University
  • The Royal Marsden NHS Foundation Trust
  • Thermo Fisher Scientific
  • Third Rock Ventures
  • Thomas Jefferson University
  • Tizona Therapeutics
  • Touchstone Innovations
  • U.S. Venture Partners
  • uBiome
  • UbiQ
  • UCSF Helen Diller Family Comprehensive Cancer Center
  • University College London Cancer Institute
  • University Hospital Complex of A Coruña
  • University Hospital Frankfurt
  • University of Bergen
  • University of California
  • University of Castilla-La Mancha
  • University of Chicago
  • University Of Colorado
  • University of Colorado Denver
  • University of Florida
  • University of Glasgow
  • University of Health Network
  • University of Iowa
  • University of Kansas Cancer Center
  • University of Kansas Medical Center
  • University of Lodz
  • University of Macau
  • University of Miami
  • University of Miami School of Medicine
  • University of Navarra Clinic
  • University of New Mexico
  • University of Oklahoma Health Sciences Center
  • University Of Pennsylvania
  • University of Pittsburgh Cancer Institute
  • University of Rome Tor Vergata
  • University of South Alabama
  • University of Texas
  • University of Washington
  • University of Wisconsin-Madison
  • US Department of Defense
  • US Department of Health and Human Services
  • UT Southwestern Medical Center
  • UTokyo Innovation Platform
  • Vanderbilt University
  • Venrock
  • Versant Ventures
  • Vivo Capital of Palo Alto
  • Voyager Therapeutics
  • Wellcome Sanger Institute
  • Woodford Patient Capital Trust
  • Worldwide Cancer Research
  • WuXi AppTec Ventures
  • WuXi Healthcare Ventures
  • Yale School of Medicine
  • Yale University
  • Yunfeng Capital
Note: Product cover images may vary from those shown
6 of 5

 

 

Loading
LOADING...

Adroll
adroll